Epithelial to Mesenchymal Transition: A Mechanism that Fuels Cancer Radio/Chemoresistance
Open accessThe DOI matches its Crossref record; 136 of the 137 references it cites were found in a registry or an index.
Abstract
Epithelial to mesenchymal transition (EMT) contributes to tumor progression, cancer cell invasion, and therapy resistance. EMT is regulated by transcription factors such as the protein products of the SNAI gene family, which inhibits the expression of epithelial genes. Several signaling pathways, such as TGF-beta1, IL-6, Akt, and Erk1/2, trigger EMT responses. Besides regulatory transcription factors, RNA molecules without protein translation, micro RNAs, and long non-coding RNAs also assist in the initialization of the EMT gene cluster. A challenging novel aspect of EMT research is the investigation of the interplay between tumor microenvironments and EMT. Several microenvironmental factors, including fibroblasts and myofibroblasts, as well as inflammatory, immune, and endothelial cells, induce EMT in tumor cells. EMT tumor cells change their adverse microenvironment into a tumor friendly neighborhood, loaded with stromal regulatory T cells, exhausted CD8+ T cells, and M2 (protumor) macrophages. Several EMT inhibitory mechanisms are instrumental in reversing EMT or targeting EMT cells. Currently, these mechanisms are also significant for clinical use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Main EMT regulatory mechanisms. EMT is a product of internal and external events in cells. It is mainly induced by external factors, such as TGF-β1, neurotrophins, or interleukin-6, which activate several signaling pathways such as WNT, Smads, STATs, Akt, or Erk1/2. The activated pathways drive transcription factors (Goosecoid, Snail, Slug, Twist, nuclear factor erythroid-2-related factor 2 (NRF2), and Krüppel-like factors (KLFs)) to bind to special responding sequences in DNA, and, consequently, these mainly suppress the expression of genes related to epithelial differentiation. The best-known event in this process is the down-regulation of E-cadherin by the SNAI transcription factors, Snail, and Slug. At the same time, mesenchymal gene products, such as vimentin, are induced during the transcriptional changes in the EMT process, where the Smad, HIF-1α, and KLF4 transcription factors are directly involved [43,44]. The transcription regulatory process during EMT does not only rely on transcription factors, but also on long noncoding RNAs (lncRNAs) and microRNAs. The external EMT-inducing factors, such as TGF-β1, neurotrophins, or interleukin-6, are available from the fibroblastic and inflammatory microenvironment, but tumor cells also actively participate in the completion of an EMT program [45]. Based on the experimental data of several research groups, including ours, it has been found that acidic extracellular conditions and, in a further step, a low oxygen tension (hypoxia) are necessary for EMT. Interestingly, EMT tumor cells produce immune checkpoint regulatory molecules and actively remodel their immune microenvironment into a more tumor-friendly one from a hostile neighborhood.](https://figures.cochat.ai/paper-figures/d094b8bd283a4ef386664d3b8450b072/epithelial-to-mesenchymal-transition-a-mechanism-that-fuels-cancer-radio-figure-1.jpg)
![Figure 2 The TGF-β1 gradient causes heterogeneity in the tumor cell nests. There are higher TGF-β1 concentrations near the tumor vasculature, and the tumor cell nest has a decreasing gradient from its border towards the middle, which generates heterogeneity between the tumor–stroma interface and the tumor cell nest center [47]. The TGF-β1 gradient contributes to the heterogenic architecture of the tumor cell nest, where the invasive front has a completely different functional and differentiation profile than the core of the tumor cell nest. Additionally, at the invasive front, tumor cells interact with fibroblasts, leukocytes, and other stromal cells. Some scattered tumor cells undergo EMT at the tumor cell nest–stroma interface and contain both epithelial and mesenchymal markers. The figure is based on a figure published by Mayorca-Giuliani and Erler [48], which has been updated by the published data of Nieto et al. [29].](https://figures.cochat.ai/paper-figures/38bb690ce5c7436d87781e26d39438ba/epithelial-to-mesenchymal-transition-a-mechanism-that-fuels-cancer-radio-figure-2.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These include altered drug transport, e.g., overexpression of drug efflux pumps like ABC transporters, activation of cell survival signaling pathways such as PI3K/AKT, and deregulation of apoptotic pathways leading to resistance to apoptosis [76].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [76]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“Tumor-associated chronic inflammation is a hallmark of cancer [72], which fosters the progression to metastasis [37].”
BackgroundNieto, M. A., Huang, R. Y.-J., Jackson, R. A., & Thiery, J. P. (2016) · Cell · doi:10.1016/j.cell.2016.06.028 · Cited by 4,492
Gregory, P. A., Bert, A. G., Paterson, E. L., Barry, S. C., Tsykin, A., Farshid, G., Vadas, M. A., Khew-Goodall, Y., & Goodall, G. J. (2008) · Nature Cell Biology · doi:10.1038/ncb1722 · Cited by 3,863
Cano, A., Pérez-Moreno, M. A., Rodrigo, I., Locascio, A., Blanco, M. J., del Barrio, M. G., Portillo, F., & Nieto, M. A. (2000) · Nature Cell Biology · doi:10.1038/35000025 · Cited by 3,668
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Epithelial-Mesenchymal Transition: At the Crossroads of Development and Tumor Metastasis
Yang, J., & Weinberg, R. A. (2008) · Developmental Cell · doi:10.1016/j.devcel.2008.05.009 · Cited by 3,012 · cited 1×
“The E-cadherin promoter is hypermethylated in leukemia, which leads to the loss of this protein [56], as in the tumor cells of solid tumors, which can lose E-cadherin by down-regulating EMT [24].”
BackgroundEMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Shibue, T., & Weinberg, R. A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.44 · Cited by 2,539 · cited 1×
“Nevertheless, the EMT-TFs play even more important pleiotropic roles [4] in invasive, disseminating, and progressive cancer.”
BackgroundZheng, X., Carstens, J. L., Kim, J., Scheible, M., Kaye, J., Sugimoto, H., Wu, C.-C., LeBleu, V. S., & Kalluri, R. (2015) · Nature · doi:10.1038/nature16064 · Cited by 2,032 · cited 4×
“One option to obtain better proof is the identification of EMT cells in tumor tissue sections by selective, reliable, and sensitive immunolabelling [30].”
BackgroundInfluentialBrabletz, T., Kalluri, R., Nieto, M. A., & Weinberg, R. A. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.118 · Cited by 1,961 · cited 9×
“Importantly, both directions of trans-differentiation are reactivated in many cancer types, but a full transition from an epithelial starting point into a differentiated fibroblastic endpoint with the expression of a fibroblast surface protein or vimentin is rarely executed [2,3].”
BackgroundInfluentialStructure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
Aller, S. G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P. M., Trinh, Y. T., Zhang, Q., Urbatsch, I. L., et al. (2009) · Science · doi:10.1126/science.1168750 · Cited by 1,929 · cited 1×
“EMT cells overexpress the ABC transporters [97,98].”
Fischer, K. R., Durrans, A., Lee, S., Sheng, J., Li, F., Wong, S. T. C., Choi, H., El Rayes, T., Ryu, S., Troeger, J., et al. (2015) · Nature · doi:10.1038/nature15748 · Cited by 1,791 · cited 2×
“Therefore, immunolabelling techniques of EMT markers in cancer tissue sections constitute the only way to estimate the proportion of EMT cells [2,35,36].”
BackgroundTaube, J. H., Herschkowitz, J. I., Komurov, K., Zhou, A. Y., Gupta, S., Yang, J., Hartwell, K., Onder, T. T., Gupta, P. B., Evans, K. W., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004900107 · Cited by 1,041
Krebs, A. M., Mitschke, J., Lasierra Losada, M., Schmalhofer, O., Boerries, M., Busch, H., Boettcher, M., Mougiakakos, D., Reichardt, W., Bronsert, P., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3513 · Cited by 975 · cited 1×
“In contrast, if ZEB1 was deleted in an identical pancreatic cancer model, metastasis was reduced by 40% [31].”
BackgroundBeg, M. S., Brenner, A. J., Sachdev, J., Borad, M., Kang, Y.-K., Stoudemire, J., Smith, S., Bader, A. G., Kim, S., & Hong, D. S. (2017) · Investigational New Drugs · doi:10.1007/s10637-016-0407-y · Cited by 897 · cited 1×
“MRX34 treatment with dexamethasone premedication was associated with an acceptable safety level and showed evidence of antitumor activity in a subset of patients with refractory advanced solid tumors [123].”
BackgroundEnvironment-mediated drug resistance: A major contributor to minimal residual disease
Meads, M. B., Gatenby, R. A., & Dalton, W. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2714 · Cited by 892 · cited 1×
“The exosomes are supposed to promote environmentallymediated therapy resistance [103].”
BackgroundEMT, cell plasticity and metastasis
Chaffer, C. L., San Juan, B. P., Lim, E., & Weinberg, R. A. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9648-7 · Cited by 861 · cited 1×
“These newer findings argue for at least a partial dispensability of EMT-TFs for the metastatic mechanism, but phenotypic plasticity still seems to be necessary for metastasis [2,33].”
BackgroundTargeting Epithelial–Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer
Du, B., & Shim, J. (2016) · Molecules · doi:10.3390/molecules21070965 · Cited by 807 · cited 12×
“W ile the importance of EMT-TFs in metastasis is controversial [2,42], they are clearly related to cancer drug resistance [42].”
BackgroundInfluentialGrande, M. T., Sánchez-Laorden, B., López-Blau, C., De Frutos, C. A., Boutet, A., Arévalo, M., Rowe, R. G., Weiss, S. J., López-Novoa, J. M., & Nieto, M. A. (2015) · Nature Medicine · doi:10.1038/nm.3901 · Cited by 783
Labernadie, A., Kato, T., Brugués, A., Serra-Picamal, X., Derzsi, S., Arwert, E., Weston, A., González-Tarragó, V., Elosegui-Artola, A., Albertazzi, L., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3478 · Cited by 747 · cited 1×
“Nevertheless, a new report describes the dissemination of squamous cell carcinoma cells, attached to tumor fibroblasts, as epithelial–mesenchymal couples, which allows epithelial and not mesenchymal transdifferentiated cells to enter the metastasis process [28,34].”
BackgroundDistinct EMT programs control normal mammary stem cells and tumour-initiating cells
Ye, X., Tam, W. L., Shibue, T., Kaygusuz, Y., Reinhardt, F., Ng Eaton, E., & Weinberg, R. A. (2015) · Nature · doi:10.1038/nature14897 · Cited by 694 · cited 1×
“For example, Slug (SNAI2), which is a member of the SNAI EMT-TF family, functions as a master regulator and allows cells to enter into the tumor-initiating cell state [59].”
BackgroundBremnes, R. M., Dønnem, T., Al-Saad, S., Al-Shibli, K., Andersen, S., Sirera, R., Camps, C., Marinez, I., & Busund, L.-T. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f8a1bd · Cited by 691 · cited 2×
“ese cells i teract it t r cells a support their proliferative and invasive behavior [90].”
BackgroundBeltran, M., Puig, I., Peña, C., García, J. M., Álvarez, A. B., Peña, R., Bonilla, F., & de Herreros, A. G. (2008) · Genes & Development · doi:10.1101/gad.455708 · Cited by 677
Inflammation and EMT: an alliance towards organ fibrosis and cancer progression
López‐Novoa, J. M., & Nieto, M. A. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900043 · Cited by 654 · cited 5×
“S e f t ese ‘ fi r lastic’ s i t eri e fr carci a cells er i [37].”
BackgroundInfluentialEMT and inflammation: inseparable actors of cancer progression
Suarez‐Carmona, M., Lesage, J., Cataldo, D., & Gilles, C. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12095 · Cited by 566 · cited 2×
“These interactive events sustain each other and ally with each other to induce metastasis [73].”
BackgroundThe Fallacy of Epithelial Mesenchymal Transition in Neoplasia
Tarin, D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0699 · Cited by 531 · cited 3×
“This lack of understanding has induced skepticism regarding the significance of the EMT hypothesis in relation to the tumor metastasis process, which was first discussed by David Tarin in 2005 [27] and placed into context in a comprehensive review article by Nieto et al.”
BackgroundMethodMicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer
Zhang, L., Liao, Y., & Tang, L. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1059-5 · Cited by 510 · cited 2×
“NCT01829971 MRX34 miRNA II miRNA-related regulation solid tumors refractory to standard treatment fatigue, back pain, diarrhea, lymphopenia, neutropenia PR, SD dexamethasone pretreatment required Zhang, Liao Tang 2019 [122]”
BackgroundMorris, J. C., Tan, A. R., Olencki, T. E., Shapiro, G. I., Dezube, B. J., Reiss, M., Hsu, F. J., Berzofsky, J. A., & Lawrence, D. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090353 · Cited by 487
TGF-β Promotes Heterogeneity and Drug Resistance in Squamous Cell Carcinoma
Oshimori, N., Oristian, D., & Fuchs, E. (2015) · Cell · doi:10.1016/j.cell.2015.01.043 · Cited by 471
Lou, Y., Diao, L., Cuentas, E. R. P., Denning, W. L., Chen, L., Fan, Y. H., Byers, L. A., Wang, J., Papadimitrakopoulou, V. A., Behrens, C., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1434 · Cited by 438 · cited 1×
“In lung adenocarcinomas with an EMT phenotype, the co-existence of immune activation with the elevation of multiple targetable immune checkpoint molecules, including PD-L1, PD-L2, PD-1, TIM-3, B7-H3, BTLA, and CTLA-4, together with an increase in their infiltration by CD4+Foxp3+ regulatory T cells, was observed [79].”
BackgroundTransformations between epithelium and mesenchyme: Normal, pathological, and experimentally induced
Hay, E. D., & Zuk, A. (1995) · American Journal of Kidney Diseases · doi:10.1016/0272-6386(95)90610-x · Cited by 423 · cited 2×
“However, trans-differentiations of epithelium into mesenchyme (EMT) and of mesenchyme into epithelium (MET) occur during embryonic development [1].”
BackgroundSaxena, M., Stephens, M. A., Pathak, H., & Rangarajan, A. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.61 · Cited by 408 · cited 15×
“Moreover, EMT-TFs are also activated in non-epithelial tumors, such as leukemia [6].”
BackgroundInfluentialEpithelial-mesenchymal transition of tubular epithelial cells in human renal biopsies
Rastaldi, M. P., Ferrario, F., Giardino, L., Dell'Antonio, G., Grillo, C., Grillo, P., Strutz, F., Müller, G. A., Colasanti, G., & D'Amico, G. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00430.x · Cited by 406 · cited 1×
“During kidney fibrosis, TECs trans-differentiate into collagen-producing cells, which are phenotypically similar to myofibroblasts [17].”
BackgroundEMT and MET in Metastasis: Where Are the Cancer Stem Cells?
Brabletz, T. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.11.009 · Cited by 403 · cited 3×
“Increasingly, scholars are arguing that the most important event in EMT is the induction of EMT-TFs, which play important roles in solid tumors as well as in leukemia [2,5].”
BackgroundEpithelial-to-Mesenchymal Transition Contributes to Immunosuppression in Breast Carcinomas
Dongre, A., Rashidian, M., Reinhardt, F., Bagnato, A., Keckesova, Z., Ploegh, H. L., & Weinberg, R. A. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3292 · Cited by 395 · cited 1×
“In contrast, tumors with a mesenchymal gene expression pattern express low levels of MHC-I, high levels of PD-L1, and contain regulatory T cells, M2 (protumor) macrophages, and exhausted CD8+ T cells [78].”
BackgroundNawshad, A., LaGamba, D., Polad, A., & Hay, E. D. (2005) · Cells Tissues Organs · doi:10.1159/000084505 · Cited by 327
Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion
Jiang, Y., & Zhan, H. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.10.013 · Cited by 319 · cited 2×
“This complex relationship between EMT and PD-L1 signaling plays an important role in the immune evasion of the tumors [80].”
BackgroundA phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients
Flaig, T. W., Gustafson, D. L., Su, L.-J., Zirrolli, J. A., Crighton, F., Harrison, G. S., Pierson, A. S., Agarwal, R., & Glodé, L. M. (2007) · Investigational New Drugs · doi:10.1007/s10637-006-9019-2 · Cited by 315 · cited 3×
“Taking the efficiency of the silibinin-containing phytosome into consideration, no objective PSA responses were observed [115].”
BackgroundResultInfluentialEMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer
Wang, L., Saci, A., Szabo, P. M., Chasalow, S. D., Castillo-Martin, M., Domingo-Domenech, J., Siefker-Radtke, A., Sharma, P., Sfakianos, J. P., Gong, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05992-x · Cited by 313
EMT and Cancer: More Than Meets the Eye
Derynck, R., & Weinberg, R. A. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.04.026 · Cited by 313 · cited 8×
“This is a reversible transition, which is reverted by MET [3].”
BackgroundInfluentialHypoxia induced EMT: A review on the mechanism of tumor progression and metastasis in OSCC
Joseph, J. P., Harishankar, M. K., Pillai, A. A., & Devi, A. (2018) · Oral Oncology · doi:10.1016/j.oraloncology.2018.03.004 · Cited by 282 · cited 2×
“Hypoxia also triggers EMT in several types of cancer, including breast, prostate, and oral cancer [70].”
BackgroundPoser, I., Domı́nguez, D., de Herreros, A. G., Varnai, A., Buettner, R., & Bosserhoff, A. K. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011224200 · Cited by 280 · cited 1×
“Snail directly binds to responsive E-box sequences in the E-cadherin (CDH1) promoter [65].”
BackgroundColeman, R., Finkelstein, D. M., Barrios, C., Martin, M., Iwata, H., Hegg, R., Glaspy, J., Periañez, A. M., Tonkin, K., Deleu, I., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30687-4 · Cited by 261 · cited 1×
“This trial in breast cancer hypothesized a potential for interfering with bone metastasis or disease recurrence in patients with early-stage breast cancer, whereas denosumab, in a clinical trial including 4509 patients, did not improve disease-related outcomes [113].”
BackgroundMarie-Egyptienne, D. T., Lohse, I., & Hill, R. P. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.11.019 · Cited by 256 · cited 2×
“Hypoxia has shared signal pathways with EMT and provides tumor cells with a stem cell-like property [108].”
BackgroundNoman, M. Z., Janji, B., Abdou, A., Hasmim, M., Terry, S., Tan, T. Z., Mami-Chouaib, F., Thiery, J. P., & Chouaib, S. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1263412 · Cited by 253 · cited 1×
“Besides the potential application of the evaluation of the EMT status as a predictive marker for checkpoint agents, these results suggest that therapies aiming at the reversal of the EMT process may potentiate the efficacy of this type of cancer immunotherapy [86,87].”
BackgroundToden, S., Okugawa, Y., Jascur, T., Wodarz, D., Komarova, N. L., Buhrmann, C., Shakibaei, M., Boland, C. R., & Goel, A. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv006 · Cited by 248 · cited 1×
“Curcumin-sensitized colorectal cancer cells were resistant to 5-fluorouracil through the miRNA-mediated suppression of EMT [130].”
BackgroundTian, X.-P., Wang, C.-Y., Jin, X.-H., Li, M., Wang, F.-W., Huang, W.-J., Yun, J.-P., Xu, R.-H., Cai, Q.-Q., & Xie, D. (2019) · Theranostics · doi:10.7150/thno.30958 · Cited by 246 · cited 1×
“Moreover, the acidic microenvironment also triggers the activation of hypoxia-related transcription factors, such as HIF-1α and HIF-2α, which stimulate exosomal expression and the release of miR-21 and miR-10b [69].”
BackgroundStavropoulou, V., Kaspar, S., Brault, L., Sanders, M. A., Juge, S., Morettini, S., Tzankov, A., Iacovino, M., Lau, I.-J., Milne, T. A., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.011 · Cited by 236 · cited 1×
“For example, the knockdown of ZEB1 in a leukemia model drastically reduced the blast invasion [57].”
BackgroundTransient SNAIL1 Expression Is Necessary for Metastatic Competence in Breast Cancer
Tran, H. D., Luitel, K., Kim, M., Zhang, K., Longmore, G. D., & Tran, D. D. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0923 · Cited by 233 · cited 1×
“Moreover, if SNAI1 was deleted in a genetically engineered breast cancer model, metastasis was impaired without compensation [32].”
BackgroundChan, N., Willis, A., Kornhauser, N., Ward, M. M., Lee, S. B., Nackos, E., Seo, B. R., Chuang, E., Cigler, T., Moore, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1326 · Cited by 231
Role of the MRP1/ABCC1 Multidrug Transporter Protein in Cancer
Munoz, M., Henderson, M., Haber, M., & Norris, M. (2007) · IUBMB Life · doi:10.1080/15216540701736285 · Cited by 226 · cited 1×
“EMT cells overexpress the ABC transporters [97,98].”
Ruscetti, M., Quach, B., Dadashian, E. L., Mulholland, D. J., & Wu, H. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3476 · Cited by 225 · cited 2×
“Therefore, immunolabelling techniques of EMT markers in cancer tissue sections constitute the only way to estimate the proportion of EMT cells [2,35,36].”
BackgroundRibosome biogenesis during cell cycle arrest fuels EMT in development and disease
Prakash, V., Carson, B. B., Feenstra, J. M., Dass, R. A., Sekyrova, P., Hoshino, A., Petersen, J., Guo, Y., Parks, M. M., Kurylo, C. M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10100-8 · Cited by 221 · cited 1×
“Our own experimental data [20,23–26], in agreement with the reports of other authors, suggest that EMT might be a coincidental interplay of external initiating factors and intracellular supporting metabolic conditions [39].”
ResultVazquez-Martin, A., Oliveras-Ferraros, C., Cufí, S., Del Barco, S., Martin-Castillo, B., & Menendez, J. A. (2010) · Cell Cycle · doi:10.4161/cc.9.18.13131 · Cited by 205
Organization and fine structure of epithelium and mesenchyme in the developing chick embryo
Hay, E. D. (1968) · Cited by 205
TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma
Kupferman, M. E., Jiffar, T., El-Naggar, A., Yilmaz, T., Zhou, G., Xie, T., Feng, L., Wang, J., Holsinger, F. C., Yu, D., et al. (2010) · Oncogene · doi:10.1038/onc.2009.486 · Cited by 200 · cited 1×
“Microenvironmental components and infiltrating inflammatory cells are able to provide mediators, such as TGF-β1 [24] neurotrophins, as brain-derived neurotrophic factor [20,23,105], which transform epithelial cancer cells into EMT cells.”
BackgroundKanai, M., Otsuka, Y., Otsuka, K., Sato, M., Nishimura, T., Mori, Y., Kawaguchi, M., Hatano, E., Kodama, Y., Matsumoto, S., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2151-8 · Cited by 198
Flaig, T. W., Glodé, M., Gustafson, D., van Bokhoven, A., Tao, Y., Wilson, S., Su, L., Li, Y., Harrison, G., Agarwal, R., et al. (2010) · The Prostate · doi:10.1002/pros.21118 · Cited by 193 · cited 2×
“Silibinin’s inability to penetrate tissue may be explained by its short half-life, the brief treatment duration [119], or a yet unknown active process that removes silibinin from the prostate [119].”
BackgroundPeña, C., García, J. M., Silva, J., García, V., Rodríguez, R., Alonso, I., Millán, I., Salas, C., de Herreros, A. G., Muñoz, A., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi366 · Cited by 191
Feng, R., Morine, Y., Ikemoto, T., Imura, S., Iwahashi, S., Saito, Y., & Shimada, M. (2018) · Cell Communication and Signaling · doi:10.1186/s12964-018-0262-x · Cited by 189 · cited 3×
“This interaction might also be responsible for increasing EMT in cancer cells through paracrine VEGF [74].”
BackgroundThe relevance of the TGF-β Paradox to EMT-MET programs
Morrison, C. D., Parvani, J. G., & Schiemann, W. P. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.02.048 · Cited by 183
Arrieta, O., Barrón, F., Padilla, M.-Á. S., Avilés-Salas, A., Ramírez-Tirado, L. A., Arguelles Jiménez, M. J., Vergara, E., Zatarain-Barrón, Z. L., Hernández-Pedro, N., Cardona, A. F., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.2553 · Cited by 179 · cited 1×
“, in 2019 [129], reported the results of a phase II clinical trial, considering a combination of metformin and EGFR tyrosine kinase inhibitors (Table 1) in advanced lung adenocarcinoma.”
BackgroundKlf4 Is a Transcriptional Regulator of Genes Critical for EMT, Including Jnk1 (Mapk8)
Tiwari, N., Meyer-Schaller, N., Arnold, P., Antoniadis, H., Pachkov, M., van Nimwegen, E., & Christofori, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057329 · Cited by 165 · cited 2×
“At the same time, mesenchymal gene products, such as vimentin, are induced during the transcriptional changes in the EMT process, where the Smad, HIF-1α, and KLF4 transcription factors are directly involved [43,44].”
BackgroundSlug Confers Resistance to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
Chang, T.-H., Tsai, M.-F., Su, K.-Y., Wu, S.-G., Huang, C.-P., Yu, S.-L., Yu, Y.-L., Lan, C.-C., Yang, C.-H., Lin, S.-B., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201009-1440oc · Cited by 163 · cited 1×
“Apoptosis resistance is one possible mechanism by which EMT contributes to cancer drug resistance [96].”
BackgroundExploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy
Micke, P., & Östman, A. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.6.1217 · Cited by 162 · cited 5×
“The external EMT-inducing factors, such as TGF-β1, neurotrophins, or interleukin-6, are available from the fibroblastic and inflammatory microenvironment, but tumor cells also actively participate in the completion of an EMT program [45].”
BackgroundInfluentialLONG, X., YE, Y., ZHANG, L., LIU, P., YU, W., WEI, F., REN, X., & YU, J. (2016) · International Journal of Oncology · doi:10.3892/ijo.2015.3234 · Cited by 153 · cited 1×
“The main inflammation-related cytokines in this system are: the tumor necrosis factor (TNF)-α [76], interleukin-8 [77], and interferon (IFN)-γ [76].”
BackgroundGuan, J., Zhang, H., Wen, Z., Gu, Y., Cheng, Y., Sun, Y., Zhang, T., Jia, C., Lu, Z., & Chen, J. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.12.006 · Cited by 152 · cited 2×
“These fibroblasts allow tumor cells to undergo EMT through the secretion of cytokines, such as interleukin-6 an t e ai i cer, - 1 [20,24,38,91,92].”
BackgroundA gene regulatory network to control EMT programs in development and disease
Fazilaty, H., Rago, L., Youssef, K. K., Ocaña, O. H., García-Asencio, F., Arcas, A., Galcerán, J., & Nieto, M. A. (2019) · Nature Communications · doi:10.1038/s41467-019-13091-8 · Cited by 148 · cited 3×
“The mesenchymal cells are able to migrate to the metastatic location, but Prrx1 must be down-regulated again during the course of MET in order to allow the docked metastatic cells to colonize at the secondary localization [40].”
BackgroundThompson, J. C., Hwang, W.-T., Davis, C., Deshpande, C., Jeffries, S., Rajpurohit, Y., Krishna, V., Smirnov, D., Verona, R., Lorenzi, M. V., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2019.10.012 · Cited by 136
Tato-Costa, J., Casimiro, S., Pacheco, T. R., Pires, R., Fernandes, A., Alho, I., Pereira, P., Costa, P., Castelo, H. B., Ferreira, J. A., et al. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2015.09.003 · Cited by 126 · cited 6×
“A sequential set of chemotherapy treatments or a series of irradiation treatments of pure epithelial cancer cell cultures induce resistant cells that also share the EMT phenotype [101,102,104,107].”
BackgroundInfluentialNan, K.-J. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1197 · Cited by 123
Zhao, Z., Cheng, X., Wang, Y., Han, R., Li, L., Xiang, T., He, L., Long, H., Zhu, B., & He, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095884 · Cited by 122 · cited 10×
“EMT is associated with a core transcription signature, characterized by the down-regulation of E-cadherin and the up-regulation of SNAIL, ZEB, and TWIST TFs (Figure 1).”
BackgroundInfluentialEpithelial–Mesenchymal Transition Induces an Antitumor Immune Response Mediated by NKG2D Receptor
López-Soto, A., Huergo-Zapico, L., Galván, J. A., Rodrigo, L., de Herreros, A. G., Astudillo, A., & Gonzalez, S. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202950 · Cited by 111 · cited 1×
“In addition to T-cell-based immune responses, EMT has also been implicated in influencing tumor cell sensitivity to macrophages and natural killer cells [88].”
BackgroundPD-L1 Expression Promotes Epithelial to Mesenchymal Transition in Human Esophageal Cancer
Chen, L., Xiong, Y., Li, J., Zheng, X., Zhou, Q., Turner, A., Wu, C., Lu, B., & Jiang, J. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000480000 · Cited by 109 · cited 1×
“The communication between EMT and PD-L1 expression in cancer cells, as was also found in other studies [44,45,80,81], is bidirectional, in which EMT transcription factors up-regulate the expression of PD-L1, while the latter, in turn, can promote the EMT process.”
BackgroundRodón, J., Carducci, M., Sepulveda-Sánchez, J. M., Azaro, A., Calvo, E., Seoane, J., Braña, I., Sicart, E., Gueorguieva, I., Cleverly, A., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-014-0192-4 · Cited by 108
Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer
Agnihotri, N., Kumar, S., & Mehta, K. (2013) · Breast Cancer Research · doi:10.1186/bcr3371 · Cited by 108 · cited 15×
“The tumor relapse can be explained by the mesenchymal transdifferentiated subpopulations of cancer cell nests that are induced by the fibroblastic stroma and are readily radio-resistant and chemo-resistant [106].”
BackgroundInfluentialLi, X. L., Hara, T., Choi, Y., Subramanian, M., Francis, P., Bilke, S., Walker, R. L., Pineda, M., Zhu, Y., Yang, Y., et al. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01043-13 · Cited by 101
Sommers, C. L., Heckford, S. E., Skerker, J. M., Worland, P. J., Torri, J. A., Thompson, E. W., Byers, S. W., & Gelmann, E. P. (1992) · PubMed · Cited by 96
Context-specific roles of EMT programmes in cancer cell dissemination
Nieto, M. A. (2017) · Nature Cell Biology · doi:10.1038/ncb3520 · Cited by 96 · cited 2×
“The genetic deletion of SNAI1 and TWIST1 EMT-TFs in a pancreatic cancer model revealed that the loss of these EMT-TFs did not reduce metastasis but increased chemosensitivity [2,28,30].”
BackgroundMa, M., Xu, H., Liu, G., Wu, J., Li, C., Wang, X., Zhang, S., Xu, H., Ju, S., Wei, C., et al. (2019) · Hepatology · doi:10.1002/hep.30602 · Cited by 94 · cited 3×
“The finding that MITA1 also regulates EMT, in addition to external factors, such as TGF-β1, is a significant step in EMT research and offers an insight into the complexity of EMT regulation through the interaction of inner and external contributors [67].”
BackgroundCarbonic anhydrase IX inhibition affects viability of cancer cells adapted to extracellular acidosis
Andreucci, E., Peppicelli, S., Carta, F., Brisotto, G., Biscontin, E., Ruzzolini, J., Bianchini, F., Biagioni, A., Supuran, C. T., & Calorini, L. (2017) · Journal of Molecular Medicine · doi:10.1007/s00109-017-1590-9 · Cited by 92 · cited 2×
“The altered metabolism in tumor cell nests results not only in an acidic microenvironment, but also in hypoxia (Figures 1 and 2) [68].”
BackgroundMicroarray analysis of gene expression during epithelial–mesenchymal transformation
LaGamba, D., Nawshad, A., & Hay, E. D. (2005) · Developmental Dynamics · doi:10.1002/dvdy.20489 · Cited by 87 · cited 2×
“Nawshad [10], investigated the rapid morphological changes in a developing mouse palate, where they isolated the medial edge epithelium, without contamination of the surrounding mesenchymal cells.”
BackgroundSui, H., Zhu, L., Deng, W., & Li, Q. (2014) · Oncology Research and Treatment · doi:10.1159/000367802 · Cited by 86 · cited 2×
“These fibroblasts allow tumor cells to undergo EMT through the secretion of cytokines, such as interleukin-6 an t e ai i cer, - 1 [20,24,38,91,92].”
BackgroundZhang, S., Mercado-Uribe, I., Hanash, S., & Liu, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080120 · Cited by 86 · cited 8×
“They described a profile of differentially regulated proteins in giant cells in response to hypoxia, stem cell generation, chromatin remodeling, cell cycle regulation, invasion, and metastasis [110].”
BackgroundInfluentialNovel clinical therapeutics targeting the epithelial to mesenchymal transition
Kothari, A. N., Mi, Z., Zapf, M. A. C., & Kuo, P. C. (2014) · Clinical and Translational Medicine · doi:10.1186/s40169-014-0035-0 · Cited by 84 · cited 2×
“In 2014, Kothari, Ki, Zapf, and Kuo [124] reviewed the development of compounds that target EMT.”
BackgroundDudás, J., Bitsche, M., Schartinger, V. H., Falkeis, C., Sprinzl, G. M., & Riechelmann, H. (2010) · Oral Oncology · doi:10.1016/j.oraloncology.2010.11.002 · Cited by 82 · cited 3×
“These fibroblasts allow tumor cells to undergo EMT through the secretion of cytokines, such as interleukin-6 an t e ai i cer, - 1 [20,24,38,91,92].”
BackgroundSelf-citationMesenchymal transition in kidney collecting duct epithelial cells
Ivanova, L., Butt, M. J., & Matsell, D. G. (2008) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00326.2007 · Cited by 81
Involvement of epithelial-mesenchymal transition in liver fibrosis
Li, N., Yu, K., Li, Q., & Shi, G. (2018) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_297_17 · Cited by 80 · cited 2×
“Several years later [18], the EMT hypothesis was also proposed in relation to the liver, which suggests that hepatocytes may develop a (myo)fibroblastic phenotype and contribute to fibrogenesis [13].”
BackgroundTargeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974
Boone, J. D., Arend, R. C., Johnston, B. E., Cooper, S. J., Gilchrist, S. A., Oelschlager, D. K., Grizzle, W. E., McGwin, G., Gangrade, A., Straughn, J. M., et al. (2015) · Laboratory Investigation · doi:10.1038/labinvest.2015.150 · Cited by 79
Zang, C., Liu, X., Li, B., He, Y., Jing, S., He, Y., Wu, W., Zhang, B., Ma, S., Dai, W., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14495 · Cited by 79 · cited 1×
“reported that STAT3 inhibition or Twist depletion reversed the EMT process and attenuated radio-resistance [51].”
BackgroundSun, H., Peng, Z., Tang, H., Xie, D., Jia, Z., Zhong, L., Zhao, S., Ma, Z., Gao, Y., Zeng, L., et al. (2017) · Oncogene · doi:10.1038/onc.2016.447 · Cited by 79
Noman, M. Z., Van Moer, K., Marani, V., Gemmill, R. M., Tranchevent, L.-C., Azuaje, F., Muller, A., Chouaib, S., Thiery, J. P., Berchem, G., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1345415 · Cited by 78 · cited 1×
“Besides the potential application of the evaluation of the EMT status as a predictive marker for checkpoint agents, these results suggest that therapies aiming at the reversal of the EMT process may potentiate the efficacy of this type of cancer immunotherapy [86,87].”
BackgroundRole of cell-matrix contacts in cell migration and epithelial-mesenchymal transformation
Hay, E. D. (1990) · Cell Differentiation and Development · doi:10.1016/0922-3371(90)90052-x · Cited by 77 · cited 3×
“The publications of Elisabeth Hay were the first to highlight these transition processes [8] in embryonic development, organ pathologies, and tumor cell metastasis [9].”
BackgroundLin, J., Tsai, J.-T., Chao, T.-Y., Ma, H.-I., & Liu, W. (2018) · Cancers · doi:10.3390/cancers10120512 · Cited by 70 · cited 14×
“A sequential set of chemotherapy treatments or a series of irradiation treatments of pure epithelial cancer cell cultures induce resistant cells that also share the EMT phenotype [101,102,104,107].”
BackgroundInfluentialSkvortsova, I., Skvortsov, S., Raju, U., Stasyk, T., Riesterer, O., Schottdorf, E.-M., Popper, B., Schiestl, B., Eichberger, P., Debbage, P. L., et al. (2010) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2010.04.017 · Cited by 65
Cuyàs, E., Pérez-Sánchez, A., Micol, V., Menéndez, J. A., & Bosch‐Barrera, J. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1245249 · Cited by 65 · cited 11×
“However, recent studies investigating gene expression signatures, predicting the efficacy of PD-1/PD-L1 inhibitors in different cancer types, found that tumors with EMT or the mesenchymal phenotype showed a lower response rate [83–85].”
BackgroundInfluentialSlug is a key mediator of hypoxia induced cadherin switch in HNSCC: Correlations with poor prognosis
Zhang, J., Cheng, Q., Zhou, Y., Wang, Y., & Chen, X. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2013.08.003 · Cited by 64 · cited 4×
“In conclusion, the association of Slug and HIF seems to be proven in HNSCC and the data of Zhang and colleagues suggest that Slug and HIF-1 are potential risk markers predicting the clinical outcome of HNSCC [71].”
BackgroundInfluentialGhosh, R. D., Ghuwalewala, S., Das, P. K., Mandloi, S., Alam, S. K., Chakraborty, J., Sarkar, S., Chakrabarti, S., Panda, C. K., & Roychoudhury, S. (2016) · Scientific Reports · doi:10.1038/srep23932 · Cited by 64 · cited 9×
“In this case, the resistant cells exhibit an enhanced proliferative, clonogenic capacity, with a significant up-regulation of P-glycoprotein (ABCB1), c-Myc, survivin, and beta-catenin and a putative cancer-stem-like signature, with an increased expression of CD44, whereas they display a loss of E-cadherin [100].”
BackgroundInfluentialZhou, Z., Peng, Y., Wu, X., Meng, S., Yu, W., Zhao, J., Zhang, H., Wang, J., & Li, W. (2019) · Cellular Oncology · doi:10.1007/s13402-018-0410-8 · Cited by 60 · cited 1×
“Direct evidence also suggests that M2 macrophages produce cytokines, such as CCL18, which support EMT and the invasion and migration of tumor cells [75].”
BackgroundAdhesion Deregulation in Acute Myeloid Leukaemia
Gruszka, A., Valli, D., Restelli, C., & Alcalay, M. (2019) · Cells · doi:10.3390/cells8010066 · Cited by 59 · cited 5×
“Moreover, EMT-TFs are also activated in non-epithelial tumors, such as leukemia [6].”
BackgroundInfluentialAcute myeloid leukemia in the vascular niche
Cogle, C. R., Bosse, R. C., Brewer, T. M., Migdady, Y., Shirzad, R., Kampen, K. R., & Saki, N. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.05.007 · Cited by 57 · cited 3×
“In AML, the leukemic blasts detach from the bone marrow niches and move into the peripheral blood to colonize other sites by changing the adhesion conditions [6], which is very similar to the adhesion changes described for EMT in the Introduction [6].”
BackgroundThe potential for targeting extracellular LOX proteins in human malignancy
Erler, J. T., & Mayorca‐Guiliani, A. E. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s38110 · Cited by 57 · cited 4×
“The figure is based on a figure published by Mayorca-Giuliani and Erler [48], which has been updated by the published data of Nieto et al.”
MethodInfluentialNambiar, D. K., Rajamani, P., & Singh, R. P. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.11.069 · Cited by 56 · cited 1×
“A similar concept, known as the inhibition of IL-6/STAT3 signaling, is also achieved by silibinin, which is a plant flavonoid that entered scientific focus in recent years, based on results that describe the possibility of radio-sensitizing endothelial cells by inhibiting the expression of pro-angiogenic factors [114].”
BackgroundLiver Fibrosis: Possible Involvement of EMT
Ikegami, T., Zhang, Y., & Matsuzaki, Y. (2007) · Cells Tissues Organs · doi:10.1159/000101322 · Cited by 55
Patnaik, A., Gordon, M., Tsai, F., Papadopoulous, K., Rasco, D., Beeram, S. M., Fu, S., Janku, F., Hynes, S. M., Gundala, S. R., et al. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3623-7 · Cited by 55
Silibinin Preferentially Radiosensitizes Prostate Cancer by Inhibiting DNA Repair Signaling
Nambiar, D. K., Rajamani, P., Deep, G., Jain, A., Agarwal, R., & Singh, R. P. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0348 · Cited by 54 · cited 1×
“In vitro results suggested that silibinin enhanced the radiotherapeutic response of prostate cancer cells by suppressing ionizing radiation-induced pro-survival signaling and DNA double strand break repair pathways [118].”
BackgroundNwani, N. G., Deguiz, M. L., Jiménez, B., Vinokour, E. I., Dubrovskyi, O., Ugolkov, A. V., Mazar, A. P., & Volpert, O. V. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2468 · Cited by 54
Gilles, C., Polette, M., Piette, J., Birembaut, P., & Foidart, J. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910590514 · Cited by 54 · cited 1×
“Matrix-degrading-enzymes are dated earlier than the hypothesis that it has a role in fibrosis [1,8,9,19].”
BackgroundTeknos, T. N., Grecula, J. C., Agrawal, A., Old, M. O., Ozer, E., Carrau, R., Kang, S.-Y., Rocco, J. W., Blakaj, D. M., Diavolitsis, V. M., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0696-4 · Cited by 53 · cited 2×
“[132], in stage III IVa and IVb head and neck cancer, vorinostat with concurrent chemoradiation achieved a 96.”
BackgroundCurcumin targets fibroblast–tumor cell interactions in oral squamous cell carcinoma
Dudás, J., Fullár, A., Romani, A., Pritz, C. O., Kovalszky, I., Schartinger, V. H., Sprinzl, G. M., & Riechelmann, H. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.12.001 · Cited by 52 · cited 1×
“Our research group published one of the first reports on the preclinical effects of curcumin on EMT [22].”
BackgroundSelf-citationChen, Z., Wang, Y., Liu, W., Zhao, G., Lee, S.-C., Balogh, A., Zou, Y., Guo, Y., Zhang, Z., Gu, W., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105331 · Cited by 50 · cited 1×
“At the same time, mesenchymal gene products, such as vimentin, are induced during the transcriptional changes in the EMT process, where the Smad, HIF-1α, and KLF4 transcription factors are directly involved [43,44].”
BackgroundTang, H. M., Kuay, K. T., Koh, P. F., Asad, M., Tan, T. Z., Chung, V. Y., Lee, S. C., Thiery, J. P., & Huang, R.-J. (2016) · Cell Death Discovery · doi:10.1038/cddiscovery.2016.41 · Cited by 49 · cited 4×
“Drug discovery aims to induce EMT reversal, such as the recently proposed vorinostat [12], which is a histone deacetylase inhibitor (HDACi).”
BackgroundInfluentialMenicacci, B., Laurenzana, A., Chillà, A., Margheri, F., Peppicelli, S., Tanganelli, E., Fibbi, G., Giovannelli, L., Del Rosso, M., & Mocali, A. (2017) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glw336 · Cited by 47 · cited 2×
“Interestingly, these CAFs that support EMT in tumor cells are reported to be senescent [93], whereas normal dermal fibroblasts are able to attenuate the growth of tumor cells, which has been reported in melanoma by Nwani et al.”
BackgroundInflammatory mediators, tumor necrosis factor-α and interferon-γ, induce EMT in human PTC cell lines
Lv, N., Gao, Y., Guan, H., Wu, D., Ding, S., Teng, W., & Shan, Z. (2015) · Oncology Letters · doi:10.3892/ol.2015.3518 · Cited by 46
Relationship of Metabolic Alterations and PD-L1 Expression in Cisplatin Resistant Lung Cancer
Wangpaichitr, M., Kandemir, H., Li, Y. Y., Wu, C., Nguyen, D., Feun, L. G., Kuo, M. T., & Savaraj, N. (2017) · Cell & Developmental Biology · doi:10.4172/2168-9296.1000183 · Cited by 46 · cited 1×
“On the other hand, these findings may suggest that cisplatin-resistant EMT tumor cells could display an increased sensitivity to anti-PD-1 or anti-PD-L1 antibody treatment [82].”
BackgroundJin, Y., Xu, K., Chen, Q., Wang, B., Pan, J., Huang, S. H., Wei, Y., & Ma, H. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.11.037 · Cited by 43 · cited 1×
“PTEN-PI3K/Akt were the main components in the effect of simvastatin [50].”
BackgroundDing, X., Wang, X., Gong, Y., Ruan, H., Sun, Y., & Yu, Y. (2017) · Oncology Letters · doi:10.3892/ol.2017.5734 · Cited by 43 · cited 12×
“Snail directly binds to responsive E-box sequences in the E-cadherin (CDH1) promoter [65].”
BackgroundInfluentialTumor-associated fibroblast-conditioned medium induces CDDP resistance in HNSCC cells
Steinbichler, T. B., Metzler, V., Pritz, C., Riechelmann, H., & Dudas, J. (2016) · Oncotarget · doi:10.18632/oncotarget.6210 · Cited by 42
Self-citationAntoon, J. W., Nitzchke, A. M., Martin, E. C., Rhodes, L. V., Nam, S., Wadsworth, S. A., Salvo, V. A., Elliott, S. G., Collins‐Burow, B. M., Nephew, K. P., et al. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.1814 · Cited by 42 · cited 3×
“, for example, identified miRNA alterations associated with the development of resistance to death receptor signaling [120].”
BackgroundMethodInfluentialAntoon, J. W., Lai, R., Struckhoff, A. P., Nitschke, A., Elliott, S. G., Martin, E. C., Rhodes, L. V., Yoon, N. S., Salvo, V. A., Shan, B., et al. (2012) · Scientific Reports · doi:10.1038/srep00539 · Cited by 42 · cited 1×
“The therapy resistance contains elements of altered death receptor signaling [111], the induction of survival signaling pathways [111], the induction of DNA repair proteins [25], and cell division changes, such as senescence [107], instead of a cell division cycle, as well as the generation of giant cells by DNA repli…”
BackgroundChargari, C., Clemenson, C., Martins, I., Perfettini, J.-L., & Deutsch, E. (2013) · Drug Resistance Updates · doi:10.1016/j.drup.2013.01.001 · Cited by 39 · cited 5×
“A major player in this constructive cooperation of tumor stroma with a progressive cancer is the fibroblast component [89].”
BackgroundInfluentialRadiation Enhances the Epithelial– Mesenchymal Transition of A549 Cells via miR3591-5p/USP33/PPM1A
Lu, J., Zhong, Y., Chen, J., Lin, X., Lin, Z., Wang, N., & Lin, S. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000494238 · Cited by 39 · cited 3×
“This list can be extended with miR-3591-5p, which is the most significantly increased miRNA in response to radiation [102].”
BackgroundEpithelial-mesenchymal crosstalk induces radioresistance in HNSCC cells
Steinbichler, T. B., Alshaimaa, A., Maria, M. V., Dejaco, D., Riechelmann, H., Dudás, J., & Skvortsova, I. (2017) · Oncotarget · doi:10.18632/oncotarget.23248 · Cited by 39 · cited 4×
“One of the main contributions of fibroblasts to tumor progression is supporting the radio-resistance of tumor cells [25,38].”
BackgroundSelf-citationCurrent Advance of Therapeutic Agents in Clinical Trials Potentially Targeting Tumor Plasticity
Yang, X., Zhu, L.-C., Wang, Y., Li, Y., & Wang, D. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00887 · Cited by 35 · cited 3×
“In addition to LY2157299, fresolimumab, which is an antibody that neutralizes all TGF-β isoforms, is also being evaluated in phase I/II clinical trials [49,126] (Table 1).”
BackgroundNerve Growth Factor (NGF)—Receptor Survival Axis in Head and Neck Squamous Cell Carcinoma
Dudás, J., Dietl, W., Romani, A., Reinold, S., Glueckert, R., Schrott‐Fischer, A., Dejaco, D., Chacko, L. J., Tuertscher, R., Schartinger, V. H., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061771 · Cited by 33 · cited 1×
“Our research group is making important efforts to resolve the latter issue [21,23,38].”
BackgroundSelf-citationCorrection: Klf4 Is a Transcriptional Regulator of Genes Critical for EMT, Including Jnk1 (Mapk8)
Tiwari, N., Meyer‐Schaller, N., Arnold, P., Antoniadis, H., Pachkov, M. V., van Nimwegen, E., & Christofori, G. (2013) · PLoS ONE · doi:10.1371/annotation/121b04a1-0cbb-4e24-8a63-fc9cdd31ec76 · Cited by 31
Cao, Z., Koochekpour, S., Strup, S. E., & Kyprianou, N. (2017) · Oncotarget · doi:10.18632/oncotarget.19659 · Cited by 26 · cited 5×
“In a further study, Zang et al. reported that STAT3 inhibition or Twist depletion reversed the EMT process and attenuated radio-resistance [51].”
BackgroundInfluentialPark, H., Kim, D., Kim, D., Park, J., Koh, Y., & Yoon, S.-S. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz146 · Cited by 18 · cited 1×
“A new hypothesis argues for an EMT-like change in leukemia cells, which also includes the induction of EMT transcription factors, such as ZEB2 [2,54,55].”
BackgroundPapiewska‐Pająk, I., Kowalska, M. A., & Boncela, J. (2016) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.5604/17322693.1219401 · Cited by 17 · cited 1×
“The consequence is a direct suppression of the tight junction and gap junction proteins between epithelial cells [66].”
BackgroundConinck, S. D., Berx, G., Taghon, T., Vlierberghe, P. V., & Goossens, S. (2019) · Advances in Biological Regulation · doi:10.1016/j.jbior.2019.100639 · Cited by 16 · cited 2×
“Similar to solid tumors, in leukemia, EMT-TFs, such as TWIST, ZEB1-2, and SNAI1-2, play critical roles [6,55].”
BackgroundMetzler, V. M., Pritz, C. O., Riml, A., Romani, A., Tuertscher, R., Steinbichler, T. B., Dejaco, D., Riechelmann, H., & Dudás, J. (2017) · Tumor Biology · doi:10.1177/1010428317705507 · Cited by 14 · cited 4×
“These fibroblasts allow tumor cells to undergo EMT through the secretion of cytokines, such as interleukin-6 an t e ai i cer, - 1 [20,24,38,91,92].”
BackgroundSelf-citationBrain-Derived Neurotrophin and TrkB in Head and Neck Squamous Cell Carcinoma
Dudás, J., Riml, A., Tuertscher, R., Pritz, C. O., Steinbichler, T. B., Schartinger, V. H., Sprung, S., Glueckert, R., Schrott‐Fischer, A., Chacko, L. J., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020272 · Cited by 14 · cited 2×
“Microenvironmental components and infiltrating inflammatory cells are able to provide mediators, such as TGF-β1 [24] neurotrophins, as brain-derived neurotrophic factor [20,23,105], which transform epithelial cancer cells into EMT cells.”
BackgroundSelf-citationKidan, N., Khamaisie, H., Ruimi, N., Roitman, S., Eshel, E., Dally, N., Ruthardt, M., & Mahajna, J. A. (2017) · Journal of Cancer · doi:10.7150/jca.19633 · Cited by 13 · cited 2×
“Both are hypoxic niches that produce TGF-β1 [52].”
BackgroundResultPleiotropic Effects of Epithelial Mesenchymal Crosstalk on Head and Neck Cancer: EMT and beyond
Steinbichler, T. B., Savic, D., Dejaco, D., Romani, A., Kofler, B., Skvortsova, I., Riechelmann, H., & Dudás, J. (2019) · Cancer Microenvironment · doi:10.1007/s12307-019-00228-y · Cited by 12 · cited 6×
“Taking HNSCC as an example, fibroblasts and tumor cells are the main components of the tumor tissue, as depicted in Figure 3 [38].”
BackgroundMethodSelf-citationCosimo, S. D., Verde, N. M. L., Moretti, A., Cazzaniga, M. E., Generali, D., Bianchi, G., Mariani, L., Torri, V., Crippa, F., Paolini, B., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0220644 · Cited by 11
Sources of myofibroblasts in kidney fibrosis: All answers are correct, however to different extent!
Ballhause, T. M., Soldati, R., & Mertens, P. R. (2013) · International Urology and Nephrology · doi:10.1007/s11255-013-0626-5 · Cited by 10
Decoding the Knots of Initiation of Oncogenic Epithelial-Mesenchymal Transition in Tumor Progression
Guo, P.-D., Gao, A., Zhang, G., Han, H., & Zhou, Q. (2013) · Current Cancer Drug Targets · doi:10.2174/15680096113136660105 · Cited by 9 · cited 3×
“The interplay between microenvironmental inducing components and intracellular conditions enabling a response activates signal transduction pathways such as Ras, Myc, Bmi-1, Oct4, Nanog, Slug, Twist, Zeb1, and Zeb2 [7].”
Background
Cited by
The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis
Huang, Y., Hong, W., & Wei, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01347-8 · Cited by 1,032
Dynamic EMT: a multi‐tool for tumor progression
Brabletz, S., Schuhwerk, H., Brabletz, T., & Stemmler, M. P. (2021) · The EMBO Journal · doi:10.15252/embj.2021108647 · Cited by 761
“EMT activation in these cells is controlling therapy resistance on multiple levels (Singh & Settleman, 2010; Shibue & Wein-berg, 2017; Santamaria et al , 2019; Dudas et al , 2020).”
InfluentialTargeting macrophages in cancer immunotherapy
Duan, Z., & Luo, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00506-6 · Cited by 625
Erin, N., Grahovac, J., Brozovic, A., & Efferth, T. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100715 · Cited by 527
Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies
Kumari, N., & Choi, S. H. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02272-x · Cited by 315
“Another mechanism underpinning chemoresistance has been discovered to be the epithelial to mesenchymal transition, which can be triggered by macrophages [101, 102].”
Background
Metadata
- Authors
- Dudás, J., Ladányi, A., Ingruber, J., Steinbichler, T. B., & Riechelmann, H.
- Affiliations
- Innsbruck Medical University (AT)
- National Institute of Oncology (HU)
- Corresponding author
- Dudás, József
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2020-02-12
- Volume
- 9
- Issue
- 2
- Pages
- 428
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC7072371
- OpenAlex
- W3006507687
- Cited by
- 213
- References
- 137
- Citations by year
- 2026: 21 · 2025: 31 · 2024: 41 · 2023: 34 · 2022: 40 · 2021: 28 · 2020: 16
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Austrian Science Fund (P25869-B13, I3976-B33)
- Nemzeti Kutatási Fejlesztési és Innovációs Hivatal (ANN 128524)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Keywords
- epithelial-mesenchymal transition, cancer therapy resistance, radioresistance (biology), chemoresistance, TGF-β1 signaling, microRNA, long non-coding RNA, tumor microenvironment, cancer-associated fibroblasts, myofibroblasts, regulatory T cells, M2 macrophages, CD8+ T cell exhaustion, EMT reversal
- MeSH terms
- Antineoplastic Agents, Phytogenic, Humans, Neoplasms, Transcription Factors, Signal Transduction, Transforming Growth Factor beta, Drug Resistance, Neoplasm, Mitogen-Activated Protein Kinase 3, T-Lymphocytes, Regulatory, Epithelial-Mesenchymal Transition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.